Clinical trials: Recurrent Tumor
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma
This phase I/II trial studies the side effects and best dose of lenalidomide when given together with rituximab-ifosfamide-carboplatin-etoposide (R-ICE) and to see how well they work in treating patients with diffuse large B-cell…
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma
- Trial name
- NCT02628405
- Testing
- Carboplatin, Etoposide, Ifosfamide
- Where
- 12 sites in United States
- Volunteers
- 30 people
- Sponsor
- Academic and Community Cancer Research United
HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present
Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma
This phase I trial studies how well autologous NY-ESO-1-specific CD8-positive T lymphocytes (modified T lymphocytes [T cells]), chemotherapy, and aldesleukin with or without dendritic cell-targeting lentiviral vector ID-LV305…
- Conditions
- HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Myxoid Liposarcoma, Recurrent Synovial Sarcoma
- Trial name
- NCT03450122
- Testing
- Aldesleukin, Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Diffuse Large B-cell Lymphoma
A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOP
Patients with diffuse large B-cell lymphoma (DLBCL) who are primary refractory to first-line R-CHOP therapy or relapse within 12 months after R-CHOP have a poor prognosis and limited treatment options.
- Trial name
- NCT07702851
- Testing
- Polatuzumab vedotin, Glofitamab
- Volunteers
- 47 people
- Sponsor
- Yonsei University
Childhood Extracranial Germ Cell Tumor, Childhood Extragonadal Malignant Germ Cell Tumor
Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors
This phase II trial is studying how well giving combination chemotherapy works in treating young patients with recurrent or resistant malignant germ cell tumors.
- Conditions
- Childhood Extracranial Germ Cell Tumor, Childhood Extragonadal Malignant Germ Cell Tumor, Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant Testicular Germ Cell Tumor
- Trial name
- NCT00467051
- Testing
- Carboplatin, Filgrastim, Ifosfamide
- Where
- 95 sites in United States, Australia and 2 more
- Volunteers
- 20 people
- Sponsor
- Children's Oncology Group
Cancer, Malignancy
Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)
CAR-T is a pioneering cancer treatment which has found success in some cancers. This treatment is made first by taking blood cells from the patient.
- Conditions
- Cancer, Malignancy, Refractory Cancer, Relapsed Cancer
- Trial name
- ANGELICA (NCT05302037)
- Testing
- Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)
- Where
- Singapore
- Volunteers
- 12 people
- Sponsor
- CytoMed Therapeutics Pte Ltd
Hematologic Malignancy
Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy
This is a multi-center, open-label, dose-escalation and cohort-expansion phase I clinical study to evaluate the safety and tolerability, pharmacokinetics profile, efficacy and immunogenicity of IMM01 in subjects with refractory…
- Trial name
- NCT05860075
- Testing
- IMM01
- Where
- China
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Shoulder Injuries
Results of Distal Clavicle Graft in Shoulder Dislocation Clavicle Auto Graft in Patient With Recurrent Anterior Shoulder Dislocation
to evaluate the clinical and radiological Outcome of Distal Clavicle Auto graft in patient with recurrent Shoulder dislocation
- Trial name
- NCT06186362
- Volunteers
- 30 people
- Sponsor
- Al-Azhar University
Acoustic Schwannoma, Adult Anaplastic Meningioma
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Acoustic Schwannoma, Adult Anaplastic Meningioma, Adult Ependymoma, Adult Grade I Meningioma
- Trial name
- NCT01125046
- Testing
- bevacizumab
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Northwestern University
Genomics, Thyroid Cancer
Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk Stratification and Post-Treatment Surveillance in Fresh Thyroid Cancer Patients
Thyroid cancer is the most common endocrine malignancy, and although differentiated thyroid cancer (DTC) generally confers favorable outcomes, 10-20% of patients still face substantial postoperative risks, including local…
- Conditions
- Genomics, Thyroid Cancer, NGS
- Trial name
- NCT07532356
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Estrogen Receptor Negative, HER2/Neu Negative
Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer
This phase II trial studies how well tivantinib works in treating patients with recurrent or metastatic breast cancer. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma
- Trial name
- NCT01575522
- Testing
- Laboratory Biomarker Analysis, Tivantinib
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy given with QS21 in treating patients who have progressive prostate cancer.
- Trial name
- NCT00004929
- Testing
- MUC-2-KLH vaccine, QS21
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer
This phase II trial is studying how well ixabepilone works in treating patients with metastatic, recurrent, or unresectable kidney cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00182702
- Testing
- ixabepilone, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Cancer of Prostate
Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP
This is a phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy (ADT) with LHRH agonist or antagonist (arm A) versus anti-androgen therapy (AAT) with…
- Trial name
- SAVE (NCT03899077)
- Testing
- Apalutamide, Leuprorelin Acetate 45Mg Powder for Injection Suspension Vial, Goserelin Acetate 10.8 MG Subcutaneous Implant
- Where
- 9 sites in Belgium
- Volunteers
- 202 people
- Sponsor
- Cancer Research Antwerp
B-Cell Lymphoma Refractory, B-cell Lymphoma Recurrent
Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation
This is a phase 2, open-label, multicenter study evaluating axicabtagene ciloleucel (axi-cel) as a 2nd line therapy in patients with Relapsed/Refractory aggressive B-NHL who are ineligible to receive Autologous Stem Cell…
- Trial name
- NCT04531046
- Testing
- axicabtagene ciloleucel
- Where
- 16 sites in Belgium, France
- Volunteers
- 62 people
- Sponsor
- The Lymphoma Academic Research Organisation
Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders
This clinical trial is studying how well giving fludarabine phosphate and melphalan together with total-body irradiation followed by donor stem cell transplant works in treating patients with hematologic cancer or bone marrow…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00856388
- Testing
- fludarabine phosphate, melphalan, total-body irradiation
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Roswell Park Cancer Institute
Moderate Depression, Severe Depressive Episode Without Psychotic Symptoms
A Randomized Clinical Trial Comparing Active Versus Sham T-PEMF Headband Treatment for Depression
An 8-week, two-armed, randomized-controlled trial that examines the antidepressant effect of treatment with transcranial pulsed electromagnetic fields (T-PEMF) in patients diagnosed with moderate to severe depression using using…
- Conditions
- Moderate Depression, Severe Depressive Episode Without Psychotic Symptoms, Recurrent Depressive Disorder, Current Episode Moderate, Recurrent Depressive Disorder, Current Episode Severe Without Psychotic Symptoms
- Trial name
- NCT06005103
- Testing
- Treatment with MoodHeadBand (T-PEMF treatment)
- Where
- Denmark
- Volunteers
- 117 people
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Ulcer Foot
Transcutaneous CO₂ Therapy in Recurrent Hard-to-Heal Diabetic Foot Ulcers
Recurrent and hard-to-heal diabetic foot ulcers (DFUs) represent a clinically challenging subgroup with delayed closure and frequent non-response to standard of care (SOC).
- Trial name
- NCT07418073
- Testing
- transcutaneous application of gaseous CO2 on lower part of the body
- Where
- Slovenia
- Volunteers
- 30 people
- Sponsor
- University Medical Centre Ljubljana
Kidney Cancer
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy…
- Trial name
- NCT00027573
- Testing
- filgrastim, therapeutic allogeneic lymphocytes, cyclophosphamide
- Where
- 6 sites in United States
- Volunteers
- 36 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining SCH 66336 and gemcitabine may kill more tumor cells.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00006351
- Testing
- gemcitabine hydrochloride, lonafarnib
- Where
- Netherlands
- Volunteers
- 34 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
High-grade Glioma, Diffuse Intrinsic Pontine Glioma
IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG)
This is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in newly diagnosed and recurrent CD70+ Pediatric High-Grade Gliomas (pHGG) and Diffuse…
- Trial name
- Peds IMPACT (NCT06946680)
- Testing
- Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Florida
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.